QHP Capital Closes a $1.1 Billion Continuation Fund for Azurity

What Happened QHP Capital completed a $1.1 billion continuation fund centered on Azurity Pharmaceuticals, according to Infor Capital. The transaction allows existing investors to monetize or roll their exposure while giving the sponsor more time to compound value in a specialty pharmaceutical platform. Continuation vehicles have become an increasingly important tool in private equity, especially for businesses that remain operationally strong but would benefit from a longer hold period than a traditional fund life allows. Why GP-Led Secondaries Keep Growing Deals like Azurity show why the GP-led market continues to deepen: sellers get optional liquidity, sponsors retain ownership of favored assets, and new investors can underwrite businesses with established performance histories rather than pure underwriting projections. $1.1 billion fund size Liquidity option for legacy LPs Extended hold for a high-conviction healthcare asset In a slower exit market, continuation funds are becoming a strategic capital formation tool rather than a niche workaround. Why This Matters for Private Markets The Azurity deal reinforces the durability of GP-led secondaries as a mainstream liquidity channel. For private market participants, it is another indication that sponsors with strong assets can still generate realizations and reset ownership structures even when traditional M&A and IPO exits are uneven.